From the laboratory to the clinic: the Wilhelm Sander Foundation is providing €1.9 million in funding for 12 research projects in the fourth quarter of 2025
Basic research meets clinical application: The twelve projects funded by the Wilhelm Sander Foundation in the fourth quarter of 2025 span the spectrum from molecular mechanisms to the treatment room – from the question of how a basement membrane influences metastasis, to AI-supported tools designed to assist doctors in making treatment decisions.
New findings on treatment-resistant paediatric brain tumours
Embryonal tumours with multi-row rosettes (ETMR) are among the rarest and most aggressive brain tumours in early childhood. Despite intensive treatment, the prognosis has so far been very poor. A research project at the University of Münster, funded with €200,000 by the Wilhelm Sander Foundation and led by Prof. Kornelius Kerl, is now providing important new insights into why these tumours are particularly resistant to treatment, whilst also identifying new therapeutic targets.
Researchers are developing a therapeutic approach with few side effects to treat an aggressive form of blood cancer
Researchers led by Prof. Dr Salih from the German Consortium for Translational Cancer Research at the DKFZ’s partner site in Tübingen have, with funding of €528,000 over six years from the Wilhelm Sander Foundation, developed an innovative immunocytokine (a therapeutic antibody with a cytokine attached to it). The ‘modified immunocytokine’ (MIC molecule) specifically activates immune cells against leukaemia cells and can avoid the serious side effects triggered by previously available immunocytokines. In laboratory and animal models, the MIC molecules demonstrated strong and, above all, targeted immune activation against leukaemia – a promising step towards clinical application.
